Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature

Anghileri Elena, Castiglione Melina, Nunziata Raffaele, Boffano Carlo, Nazzi Vittoria, Acerbi Francesco, Finocchiaro Gaetano, Eoli Marica

Research output: Contribution to journalArticle

Abstract

Glioblastoma (GBM) are high-grade gliomas that severely impact on overall survival (OS). GBM cell motility and the breakdown of the blood–brain barrier could favor GBM cell communication with the systemic circulation. In spite of this, extracranial GBM metastases are rare. Here, we describe two YKL-40-positive GBM patients with extra-CNS (central nervous system) metastases, and we present a meta-analysis of 94 cases. The analysis concluded that extra-CNS metastases occurred 8.5 months after first GBM diagnosis and OS was 12 months; surgical GBM excision was associated at a longer interval to extra-CNS metastasis than biopsy only, and even longer if followed by radiotherapy and chemotherapy. Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM. At first GBM local recurrence, they were treated with bevacizumab (BV), an anti-vascular endothelial growth factor antibody. They died after 4 and 1 month from the occurrence of metastases. Both cases expressed YKL-40 and lacked EGFR amplification, suggesting a mesenchymal phenotype, and maintained such profile at extra-CNS recurrence; they did not show MGMT promoter methylation, IDH1/2 mutations, or c-Met upregulation. Our two cases and the meta-analysis support the idea that prolonged survival of GBM patients increases the probability of GBM cells shedding to lymphatic and hematic system. Interestingly, the present two cases showed the features of mesenchymal profile, usually related with worst prognosis that was maintained in extracranial metastases.

Original languageEnglish
Pages (from-to)37-46
Number of pages10
JournalNeurosurgical Review
Volume39
Issue number1
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Glioblastoma
Meta-Analysis
Neoplasm Metastasis
Survival
Recurrence
Lymphatic System
Glioma
Cell Communication
Methylation
Vascular Endothelial Growth Factor A
Cell Movement
Up-Regulation
Radiotherapy
Central Nervous System
Lymph Nodes
Phenotype
Biopsy
Drug Therapy
Lung
Mutation

Keywords

  • Bevacizumab
  • Glioblastoma (GBM)
  • Long-term survival
  • Metastases
  • YKL-40

ASJC Scopus subject areas

  • Clinical Neurology
  • Surgery

Cite this

@article{207aa5a7007541cb85d60d8124286e00,
title = "Extraneural metastases in glioblastoma patients: two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature",
abstract = "Glioblastoma (GBM) are high-grade gliomas that severely impact on overall survival (OS). GBM cell motility and the breakdown of the blood–brain barrier could favor GBM cell communication with the systemic circulation. In spite of this, extracranial GBM metastases are rare. Here, we describe two YKL-40-positive GBM patients with extra-CNS (central nervous system) metastases, and we present a meta-analysis of 94 cases. The analysis concluded that extra-CNS metastases occurred 8.5 months after first GBM diagnosis and OS was 12 months; surgical GBM excision was associated at a longer interval to extra-CNS metastasis than biopsy only, and even longer if followed by radiotherapy and chemotherapy. Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM. At first GBM local recurrence, they were treated with bevacizumab (BV), an anti-vascular endothelial growth factor antibody. They died after 4 and 1 month from the occurrence of metastases. Both cases expressed YKL-40 and lacked EGFR amplification, suggesting a mesenchymal phenotype, and maintained such profile at extra-CNS recurrence; they did not show MGMT promoter methylation, IDH1/2 mutations, or c-Met upregulation. Our two cases and the meta-analysis support the idea that prolonged survival of GBM patients increases the probability of GBM cells shedding to lymphatic and hematic system. Interestingly, the present two cases showed the features of mesenchymal profile, usually related with worst prognosis that was maintained in extracranial metastases.",
keywords = "Bevacizumab, Glioblastoma (GBM), Long-term survival, Metastases, YKL-40",
author = "Anghileri Elena and Castiglione Melina and Nunziata Raffaele and Boffano Carlo and Nazzi Vittoria and Acerbi Francesco and Finocchiaro Gaetano and Eoli Marica",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/s10143-015-0656-9",
language = "English",
volume = "39",
pages = "37--46",
journal = "Neurosurgical Review",
issn = "0344-5607",
publisher = "Springer Verlag",
number = "1",

}

TY - JOUR

T1 - Extraneural metastases in glioblastoma patients

T2 - two cases with YKL-40-positive glioblastomas and a meta-analysis of the literature

AU - Elena, Anghileri

AU - Melina, Castiglione

AU - Raffaele, Nunziata

AU - Carlo, Boffano

AU - Vittoria, Nazzi

AU - Francesco, Acerbi

AU - Gaetano, Finocchiaro

AU - Marica, Eoli

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Glioblastoma (GBM) are high-grade gliomas that severely impact on overall survival (OS). GBM cell motility and the breakdown of the blood–brain barrier could favor GBM cell communication with the systemic circulation. In spite of this, extracranial GBM metastases are rare. Here, we describe two YKL-40-positive GBM patients with extra-CNS (central nervous system) metastases, and we present a meta-analysis of 94 cases. The analysis concluded that extra-CNS metastases occurred 8.5 months after first GBM diagnosis and OS was 12 months; surgical GBM excision was associated at a longer interval to extra-CNS metastasis than biopsy only, and even longer if followed by radiotherapy and chemotherapy. Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM. At first GBM local recurrence, they were treated with bevacizumab (BV), an anti-vascular endothelial growth factor antibody. They died after 4 and 1 month from the occurrence of metastases. Both cases expressed YKL-40 and lacked EGFR amplification, suggesting a mesenchymal phenotype, and maintained such profile at extra-CNS recurrence; they did not show MGMT promoter methylation, IDH1/2 mutations, or c-Met upregulation. Our two cases and the meta-analysis support the idea that prolonged survival of GBM patients increases the probability of GBM cells shedding to lymphatic and hematic system. Interestingly, the present two cases showed the features of mesenchymal profile, usually related with worst prognosis that was maintained in extracranial metastases.

AB - Glioblastoma (GBM) are high-grade gliomas that severely impact on overall survival (OS). GBM cell motility and the breakdown of the blood–brain barrier could favor GBM cell communication with the systemic circulation. In spite of this, extracranial GBM metastases are rare. Here, we describe two YKL-40-positive GBM patients with extra-CNS (central nervous system) metastases, and we present a meta-analysis of 94 cases. The analysis concluded that extra-CNS metastases occurred 8.5 months after first GBM diagnosis and OS was 12 months; surgical GBM excision was associated at a longer interval to extra-CNS metastasis than biopsy only, and even longer if followed by radiotherapy and chemotherapy. Both our case reports were adult males who developed extra-CNS, YKL-40-positive metastases at lymph nodes, lung and subcutaneous sites, after 86 and 24 months from initial diagnosis of GBM. At first GBM local recurrence, they were treated with bevacizumab (BV), an anti-vascular endothelial growth factor antibody. They died after 4 and 1 month from the occurrence of metastases. Both cases expressed YKL-40 and lacked EGFR amplification, suggesting a mesenchymal phenotype, and maintained such profile at extra-CNS recurrence; they did not show MGMT promoter methylation, IDH1/2 mutations, or c-Met upregulation. Our two cases and the meta-analysis support the idea that prolonged survival of GBM patients increases the probability of GBM cells shedding to lymphatic and hematic system. Interestingly, the present two cases showed the features of mesenchymal profile, usually related with worst prognosis that was maintained in extracranial metastases.

KW - Bevacizumab

KW - Glioblastoma (GBM)

KW - Long-term survival

KW - Metastases

KW - YKL-40

UR - http://www.scopus.com/inward/record.url?scp=84952984733&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84952984733&partnerID=8YFLogxK

U2 - 10.1007/s10143-015-0656-9

DO - 10.1007/s10143-015-0656-9

M3 - Article

C2 - 26212701

AN - SCOPUS:84952984733

VL - 39

SP - 37

EP - 46

JO - Neurosurgical Review

JF - Neurosurgical Review

SN - 0344-5607

IS - 1

ER -